AFL
46
-3
TDC
75
4
IR
63
3
RRC
63
3
AES
39
-4
HIG
67
4
F
43
-8
LLY
39
9
MCO
73
3
GIS
26
3
MPC
47
3
FMC
31
5
CF
59
3
ILMN
32
-3
HSY
34
3
AMGN
44
5
ADP
64
2
VRTX
46
2
HRB
51
2
EXC
54
-2
AFL
46
-3
TDC
75
4
IR
63
3
RRC
63
3
AES
39
-4
HIG
67
4
F
43
-8
LLY
39
9
MCO
73
3
GIS
26
3
MPC
47
3
FMC
31
5
CF
59
3
ILMN
32
-3
HSY
34
3
AMGN
44
5
ADP
64
2
VRTX
46
2
HRB
51
2
EXC
54
-2
Financhill
Back

Arcutis Biotherapeutics 10K Form

Sell
26

ARQT
Arcutis Biotherapeutics

Last Price:
10.41
Seasonality Move:
101.78%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ARQT News And Ratings

See the #1 stock for the next 7 days that we like better than ARQT

ARQT Financial Statistics

Sales & Book Value

Annual Sales: $59.61M
Cash Flow: $-34.83M
Price / Cash Flow: 0
Annual Sales: $1.34
Price / Book: 7.05

Profitability

EPS (TTM): -1.79000
Net Income (TTM): $-195.54M
Gross Margin: $54.62M
Return on Equity: -138.99%
Return on Assets: -49.01%

Arcutis Biotherapeutics Earnings Forecast

Key Arcutis Biotherapeutics Financial Ratios

  • The Gross Profit Margin over the past 4 years for ARQT is 91.63%.
  • The Selling, General & Administrative Expenses for ARQT have been equal to 310.61% of Gross Profit Margin.
  • The Research & Development expenses have been 185.51% of Revenue.
  • The Interest Expense is -11.33% of Operating Income.
  • The Net Earning history of ARQT is -439.79% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 1 years.

Arcutis Biotherapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ARQT
CUSIP: 03969K
Website: arcutis.com

Debt

Debt-to-Equity Ratio: 1.31
Current Ratio: 2.46
Quick Ratio: 2.27

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ARQT Technical Analysis vs Fundamental Analysis

Sell
26
Arcutis Biotherapeutics (ARQT) is a Sell

Is Arcutis Biotherapeutics a Buy or a Sell?